JP Morgan Chase
TRVI icon

JP Morgan Chase’s Trevi Therapeutics TRVI Stock Holding History

JP Morgan Chase’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$91.5K – 7788
2025
Q3 		$91.5K Hold
10,000
– – ﹤0.01% 5951
2025
Q2 		$54.7K Buy
+10,000
New +$62.2K ﹤0.01% 5892

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

JP Morgan Chase's TRVI Position: Q1 2026 in Review

JP Morgan Chase increased its Trevi Therapeutics (TRVI) stake by 19% in Q1 2026, buying an estimated $125K and bringing the position to 70,631 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #4741.

JP Morgan Chase first reported a position in TRVI in Q2 2020 and has held it in 14 quarters since. The position peaked at $913K in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • JP Morgan Chase held 70,631 shares of Trevi Therapeutics worth $790K as of Q1 2026.
  • JP Morgan Chase bought 11,156 Trevi Therapeutics shares in Q1 2026, an estimated $125K.
  • Trevi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4741 holding.
  • JP Morgan Chase first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • JP Morgan Chase's Trevi Therapeutics position peaked at $913K in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.